Researchers found no association between the use of DPP-4 inhibitors, GLP-1 receptor agonists, or SGLT2 inhibitors and the risk for fracture in patients with type 2 diabetes.
Compared with the first 3 years of denosumab treatment, a longer duration of denosumab therapy was associated with further decrease in nonvertebral fracture rate, which was sustained through 10 years of treatment.
Gender-affirming hormone treatment may lead to changes in bone turnover markers in transgender men and women, but overall does not have negative effects on bone health.
Osteopenia was found in more than 25% of both men and women, suggesting that more osteoporosis screening and prevention programs are needed in middle-age individuals.
Parity and lactation had a neutral effect on the risk for fragility fractures or radiographic vertebral compression fractures over 10 years of follow-up.
Researchers used epidemiologic evidence to better understand the risk for osteoporosis and osteoarthritis in patients with cerebral palsy.
The FRAX fracture risk tool can stratify fracture risk equally well among women receiving aromatase inhibitor (AI) therapy for breast cancer and nonusers of AI therapy.
Roux-en-Y gastric bypass is associated with a higher risk for nonvertebral fractures compared with adjustable gastric banding.
Patients with or at high risk for osteoporosis should take the lowest possible dosage of vitamin D3 with the shortest possible interval.
High intake of vitamin B6 and B12 may increase the risk of hip fracture in postmenopausal women, according to the results of a recently published prospective cohort study.
Researchers identified certain factors that are associated with the use of using dual-energy x-ray absorptiometry in women within 5 years of receiving antiosteoporosis therapy.